北京若生智能科技有限公司
Drug Database
TK

TK-129 (TK 129 / TK129)

✓ Approved

Foshan Rexiu Biotechnology · LRP1

什么是 TK-129？

TK-129 是一种治疗药物，由Foshan Rexiu Biotechnology研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

商品名TK 129, TK129
公司Foshan Rexiu Biotechnology
分子靶点LRP1
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, Foshan Rexiu Biotechnology

作用机制

分子靶点

TK-129 作用于 1 个分子靶点：

LRP1LDL receptor related protein 1 (LRP1A, A2MR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

TK-129 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Rectosigmoid cancer✓ Approved

相关研究文献

PubMedJournal of mass spectrometry : JMS2026-09-10

Detailed Chemical Composition Characterization and Multicomponent Quality Control of Cyclocarya paliurus by Combining UPLC-Q-Orbitrap MS, GC-MS, and GC-IMS.

Zhu Jun J, Zhang Xinggui X, Qin Yanhua Y, Cao Fan F et al.

Cyclocarya paliurus (C. paliurus) is a novel food resource with traditional medicinal properties, including heat-clearing, detumescence, and analgesia. It has exhibited significant therapeutic effects in the treatment of metabolic diseases such as hyperglycemia, hyperlipidemia, and hypertension, making it a crucial ingredient in pharmaceutical and health food formulations. However, quality control studies focusing on the multi-component pharmacologically active substances in C. paliurus remain limited. Here, this study employed ultra-performance liquid chromatography-quadrupole-Orbitrap mass spectrometry (UPLC-Q-Orbitrap-MS), gas chromatography-mass spectrometry (GC-MS), and gas chromatography-ion mobility spectrometry (GC-IMS) technologies to profoundly characterize major pharmacologically active substances and quantitatively assess the quality of C. paliurus. A total of 88 compounds were identified from C. paliurus by UPLC-Q-Orbitrap MS, whereas 129 volatile constituents were detected through GC-MS and GC-IMS analysis. Furthermore, an adjusted parallel reaction monitoring (PRM) method was developed and validated for the quantification of eight key effective components of different types in C. paliurus, which were selected as benchmark substances for quality evaluation. In summary, this work offers a universally applicable method for identifying global metabolites and determining the multicomponent composition of complex in traditional Chinese medicine ingredients, providing a pragmatic workflow for assessing the quality and consistency.

PMID 42717421
阅读全文 →
PubMedAllergy2026-09-10

Rademikibart for Asthma With Type 2 Biomarkers: Exploratory Subgroup Analyses From a Phase 2b Randomized Clinical Trial.

Wechsler Michael E ME, Akuthota Praveen P, Quart Barry B, Collazo Raúl R

Rademikibart, an IL-4Rα-targeting antibody, demonstrated efficacy in a Phase 2b trial of adults with moderate-to-severe uncontrolled asthma (NCT04773678). We report exploratory and predominantly post hoc subgroup analyses, according to baseline eosinophil count (EOS) and fractional exhaled nitric oxide (FeNO). Patients were randomized, double-blind, to rademikibart 150 mg or 300 mg Q2W (600-mg loading) or placebo, with medium-to-high dose inhaled corticosteroids and ≥ 1 reliever/controller. Up to eight EOS/FeNO subgroups were investigated, focusing on the following five: ≥ 300 cells/μL and ≥ 25 ppb (N = 80); ≥ 25 ppb (N = 142); ≥ 300 cells/μL (N = 129); ≥ 150 cells/μL (N = 247); 150- < 300 cells/μL (N = 118). Prebronchodilator FEV1 increased significantly at first assessment (Week 1) and was sustained throughout the 24-week treatment period. FEV1 and asthma control (ACQ-6) improvements were greatest when baseline EOS and FeNO were both elevated. At Week 1, after a 600-mg loading dose, placebo-adjusted FEV1 increased by 422 mL (≥ 300 cells/μL and ≥ 25 ppb), 339 mL (≥ 25 ppb), 324 mL (≥ 300 cells/μL), 227 mL (≥ 150 cells/μL), and 141 mL (150- < 300 cells/μL). At Week 24, with 300 mg Q2W, placebo-adjusted FEV1 increased by 519 mL (≥ 300 cells/μL and ≥ 25 ppb), 401 mL (≥ 25 ppb), 394 mL (≥ 300 cells/μL), 287 mL (≥ 150 cells/μL), and 159 mL (150- < 300 cells/μL). Exacerbations decreased by ≥ 63% per subgroup. Rademikibart was well tolerated. No eosinophilia (Preferred Term) was reported. Grade 1 eosinophil count increased did not lead to treatment discontinuation (n = 2). Rapid and sustained improvements were more pronounced in patients with type 2-high biomarkers than previously reported in the overall study population.

PMID 42717393
阅读全文 →
PubMedNeurology. Education2026-09-10

Education Research: More Than a Checkbox: Implementing a Narrative-Based Child Neurology Resident Assessment System.

Latimer Christopher C, Thompson Stone Robert R, Troy Elizabeth T ET

Frequent, high-quality feedback is essential for competency-based medical education, yet many graduate medical education assessment systems rely on rating scales and infrequent assessments, limiting actionable feedback. Narrative comments, recognized for their catalytic effect, remain underutilized. The objective of this study was to design and implement a narrative-based, competency-mapped assessment system within a child neurology residency program and evaluate the feasibility of this reform. The University of Colorado Child Neurology Residency Program redesigned its assessment system in 2023, guided by the Good Assessment framework and the Accreditation Council for Graduate Medical Education Child Neurology Milestones. The new system prioritized adaptability to clinical context, narrative specificity, and integration into existing MedHub workflows. Each form required selection of a competency to assess and justification through narrative comments. Faculty development sessions introduced the structure, expectations, and strategies for writing effective narrative comments. Primary outcomes included volume of assessments and narrative comments. Secondary measures included assessor diversity, time to completion, and distribution of competency selection. We conducted a pre-post analysis comparing a 6-month preintervention period (July-December 2023) with a 6-month postintervention period (July-December 2024). In the first year of implementation, there were 13 residents. A total of 260 assessments were completed (mean 28.9 per resident), generating 816 narrative comments (mean 90.7 per resident). The median time to completion was 10.5 days (IQR 2-24). Forty-nine unique assessors contributed, including physicians (79.5%) and nonphysicians (20.5%). In the pre-post comparison, assessments increased by 129% (55 to 126), unique assessors by 106% (16 to 33), and narrative comments by 512% (49 to 300). Narrative comments addressed all mapped competencies, with Patient Care and Interpersonal Communication Skills most frequently represented. A narrative-based, adaptable assessment system is feasible to implement at scale within a child neurology residency program and substantially increases the volume of workplace-based assessments. The system diversified assessors' perspectives and produced narrative comments across all competencies without compromising timeliness. Limitations include single-site design and absence of narrative quality assessment. Future work will focus on evaluating the quality of narrative comments and acceptability of this assessment methodology.

PMID 42719678
阅读全文 →
PubMedOrthopaedic journal of sports medicine2026-09-10

Generalized Joint Laxity Is an Independent Predictor of Postoperative Resprain Following Anatomic Reconstruction Using Gracilis Tendon Autograft for Patients With Chronic Lateral Ankle Instability.

Liu Haoxuan H, Li Jianhong J, Su Tong T, Jiang Yanfang Y et al.

Generalized joint laxity (GJL) has been reported as a risk factor for poor outcomes following multiligament surgery. However, no previous studies have investigated whether GJL is a risk factor of postoperative resprain following anatomic reconstruction using gracilis tendon autograft. To investigate whether GJL is a risk factor of postoperative resprain in chronic lateral ankle instability (CLAI) patients following anatomic reconstruction using gracilis tendon autograft. Cohort study; Level of evidence, 3. A total of 290 consecutive CLAI patients who underwent anatomic reconstruction using gracilis tendon autograft from January 2018 to September 2023 with a minimum follow-up of 24 months were retrospectively evaluated and were divided into 2 groups according to the presence of GJL (based on age and Beighton score). Clinical outcomes were measured through the presence of postoperative noncontact resprain and recurrent instability, return-to-sport status, and patient-reported outcomes including the visual analog scale (VAS) for pain, Tegner Activity Level scale, and Karlsson-Peterson ankle score (Karlsson score). Risk factors associated with postoperative noncontact resprain were determined using univariate and multivariate logistic regression analysis. Survival outcomes were compared using Kaplan-Meier analysis. A total of 72 patients were included in the GJL group (mean age at surgery, 27.5 ± 9.0 years; male, n = 27; female, n = 45), and 218 patients were included in the non-GJL group (mean age at surgery, 32.8 ± 10.2 years; male, n = 129; female, n = 89). The overall noncontact resprain rate was 6.6%, and the overall recurrent instability rate was 1.7%. There was no significant difference in the postoperative VAS, Tegner, return to recreational sports rate, return to preinjury sports rate, and other surgical complications between the 2 groups. The patients with GJL demonstrated a significantly higher postoperative noncontact resprain rate (15.3% vs 3.7%; P = .001), a significantly higher postoperative recurrent instability rate (6.9% vs 0.0%; P = .001), and a significantly lower postoperative Karlsson score (90.0 ± 6.2 vs 95.6 ± 4.4; P < .001) compared with those without GJL. Multivariate logistic regression analysis revealed that GJL was an independent predictor of postoperative noncontact resprain following anatomic reconstruction using gracilis tendon autograft (P = .004; odds ratio = 4.293; 95% CI, 1.612-11.431). The cumulative success rates of the patients with GJL were significantly lower than those of the patients without GJL (P = .001). GJL is an independent predictor of postoperative noncontact resprain of CLAI patients following anatomic reconstruction using gracilis tendon autograft.

PMID 42719479
阅读全文 →
PubMedStroke and vascular neurology2026-09-09

Effects of human urinary kallidinogenase on early neurological improvement and functional outcomes in acute ischaemic stroke (TK-SPEED): protocol for a multi-centre, randomised, open-label, blinded-endpoint controlled study.

Song Xiaowei X, Qi Zhongqi Z, Gao Ceshu C, Wei Chenming C et al.

A considerable number of patients with acute ischaemic stroke (AIS) are ineligible for standard reperfusion therapy due to time window constraints and contraindications. Human urinary kallidinogenase (HUK), a tissue kallikrein, has been demonstrated to promote vasodilation and improve cerebral blood flow (CBF) in ischaemic regions. Although clinical evidence suggests its favourable efficacy in such patients with AIS, the specific effects of HUK on early cerebral perfusion and its correlation with functional outcomes remain incompletely elucidated. TK-SPEED aims to investigate the effects of HUK on early cerebral perfusion improvement and functional outcomes in patients with AIS, providing robust evidence for HUK. TK-SPEED is a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial. Approximately 540 participants with acute anterior circulation ischaemic stroke will be recruited from about 20 participating sites across China. Eligible patients will be randomly assigned in a 1:1 ratio to either the intervention group (HUK plus standard therapy) or the control group (standard therapy). The primary endpoint is the proportion of patients with a modified Rankin Scale (mRS) of 0-2 at day 90. The secondary outcomes include changes in the Tmax (time-to-maximum)>6 s volume and regional CBF in the Tmax>6 s area on CT perfusion from baseline to day 5 after treatment, the ordinal distribution of mRS, the proportion of patients with mRS of 0-1 at day 90 and changes in the National Institutes of Health Stroke Scale score from baseline to days 5 and 10 after treatment. This trial will provide crucial evidence elucidating the impact of HUK on early cerebral perfusion and its correlation with the 90-day neurological outcomes in patients with AIS, offering guidance for optimising AIS treatment strategies and improving patient prognosis. NCT06132880.

PMID 42716572
阅读全文 →
PubMedJournal of thoracic imaging2026-09-09

Real-world Performance of Computer-aided Pulmonary Nodule Detection for Lung Cancer.

DeSimone Ariadne K AK, Schulz Kathryn A KA, Byrne Suzanne C SC, Hammer Mark M MM

To evaluate the real-world sensitivity of an artificial intelligence-based pulmonary vessel suppression and computer-aided detection system (ClearRead VIS/CADe) for lung cancer detection and to characterize nodule features associated with detection and nondetection. This retrospective study included patients diagnosed with lung cancer within a lung cancer screening program in the authors' health care network after deployment of ClearRead VIS/CADe (August 2023 to June 2025). A fellowship-trained cardiothoracic radiologist reviewed the diagnosis, CT examination, and the most recent prior chest CT examination for each patient. Malignant nodules were characterized by size, type, location, and relationship to major vessels. For each examination, whether the malignant nodule was identified in the radiology report, annotated by CADe, and visible on vessel-suppressed images was recorded. Sensitivity was assessed overall and by nodule characteristics. Multivariable logistic regression was performed for nodules <30 mm to identify factors associated with CADe annotation. A total of 129 patients were included. Overall sensitivity of CADe annotation on diagnosis CT examinations was 72% (93/129), whereas vessel-suppressed images demonstrated higher sensitivity (92%, 119/129). CADe sensitivity varied significantly by nodule size (P<0.001), was highest for solid nodules (80%) and lower for part-solid (75%), ground-glass (38%), and cystic nodules (13%) (P<0.001). Vessel-suppressed images demonstrated high sensitivity across nodule sizes and morphology. After exclusion of masses, subpleural and paramediastinal locations remained independently associated with reduced sensitivity (P<0.05). Vessel-suppressed images demonstrated high sensitivity for malignant pulmonary nodules, whereas CADe performance varied by nodule type and location.

PMID 42713775
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多TK-129